Contact Us
Drug Search Results
More Filters [+]

Tetrofosmin

Alternative Names: tetrofosmin, myoview, myoview 30ml, myoview
Latest Update: 2024-12-02
Latest Update Note: News Article

Product Description

a new 99mTc-labeled myocardial perfusion imaging agent for the detection of myocardial perfusion abnormalities, with those of 201Tl and coronary angiography. (Sourced from: https://www.ahajournals.org/doi/10.1161/01.CIR.91.2.313)

Mechanisms of Action: Radioactive Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Injection

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Bulgaria | Canada | Cyprus | Czech | Finland | France | Germany | Greece | Hong Kong | Hungary | Indonesia | Ireland | Israel | Italy | Latvia | Lithuania | Malaysia | Malta | Netherlands | Norway | Peru | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tetrofosmin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

12/02/2024

News Article

 GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

09/26/2023

News Article

 Absorbable Antibacterial Suture Market Global Insights and Top Players 2023 Futura Surgicare, Healthium Medtech Limited, Meril Life Sciences

09/13/2023

News Article

 The Fluorouracil Injection market's size, share, and revenue will be scrutinized, with an anticipated CAGR of 9.9% increase from 2023 to 2030.

09/13/2023

News Article

 Epirubicin Hydrochloride Injection Market Size and Market Status Forecast growing with a CAGR of 10.1% from 2023 to 2030

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions